MEIP News and Press, MEI Pharma Inc. From 08/24/22

Summary Our US-denominated Global Micro Fund was down 16.6% in the quarter, and is down 21.0% for the year. We are taking advantage of the current turmoil in the markets, adding a new busted Biotech (KOD), and adding substantially to MEI Pharma and Liberty Tripadvisor - among othe...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, tod...

Fate Therapeutics ( NASDAQ: FATE ) has appointed Brian Powl as its new chief commercial officer . He was most recently SVP, commercial development & marketing at MEI Pharma ( MEIP ). Before then, he was VP, global commercial CAR T lead at Celgene Corp....

GreenWood Investors is a mostly-long, deep value investment firm focused on areas of extreme pessimism, structural inefficiencies and low competition. Performance of our funds was down 5.3% USD-based and 5.7% EUR-based for the first quarter, in line with global market indices down 5.5...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Fr...

3 Penny Stocks to Watch in Mid-June 2022 With another interesting day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have to consider what is going on in the stock market so we can use that to our advantage. And, over the past few days, w...

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles – – 9.9% of Patients Discontinued ...

You can’t argue that biotech stocks were hit hard during the 2022 stock market crash. But that doesn’t mean opportunity was utterly stifled. Depending on your outlook and investment style, volatility has become a considerable asset to some. You know what I’m talking abo...

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles – – 9.9% of Patients Discontinued Therapy Due...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, tod...